Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PROC Stock Forecast 2026-2027
$0.02
Current Price
$2.72M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PROC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PROC Price Momentum
0.0%
1 Week Change
-80.0%
1 Month Change
-98.6%
1 Year Change
-97.9%
Year-to-Date Change
-98.3%
From 52W High of $1.45
+2,095.5%
From 52W Low of $0.00
📊 TOP ANALYST CALLS
Did PROC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Procaps is one of their latest high-conviction picks.
Latest PROC Stock Price Targets & Analyst Predictions
PROC has shown a year-to-date change of -97.9% and a 1-year change of -98.6%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PROC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PROC Analyst Ratings
0
Buy
1
Hold
0
Sell
PROC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.02
Latest PROC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PROC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 6, 2023 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $4.50 |
Procaps Group S.A. (PROC) Competitors
The following stocks are similar to Procaps based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Procaps Group S.A. (PROC) Financial Data
Procaps Group S.A. has a market capitalization of $2.72M with a P/E ratio of 1.5x. The company generates $409.92M in trailing twelve-month revenue with a 58.4% profit margin.
Revenue growth is +7.6% quarter-over-quarter, while maintaining an operating margin of +19.1% and return on equity of -2,265.2%.
Valuation Metrics
Market Cap
$2.72M
Enterprise Value
$245.66M
P/E Ratio
1.5x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+7.6%
Gross Margin
+57.8%
Operating Margin
+19.1%
Net Margin
+58.4%
EPS Growth
+7.3%
Financial Health
Cash/Price Ratio
+709.8%
Current Ratio
1.5x
Debt/Equity
7.5x
ROE
-2,265.2%
ROA
+9.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Procaps Group S.A. (PROC) Business Model
About Procaps Group S.A.
What They Do
Develops and manufactures pharmaceutical and nutritional products.
Business Model
Procaps Group generates revenue through the development, manufacturing, and commercialization of a diverse range of pharmaceutical and nutritional products, leveraging advanced softgel technologies. The company's focus on research and development allows it to innovate and meet the needs of various sectors, including prescription and over-the-counter medications and nutritional supplements.
Additional Information
Procaps Group operates globally, supplying products to over 50 countries. Its strategic partnerships and commitment to technological advancements position it as a leader in the Latin American pharmaceutical industry, focusing on improving health outcomes and supporting disease prevention.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4,498
CEO
Mr. Ruben Minski
Country
Luxembourg
IPO Year
2019
Website
www.sofgenpharma.comProcaps Group S.A. (PROC) Latest News & Analysis
Latest News
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) will be delisted from Nasdaq due to non-compliance with reporting rules and will begin trading on the OTC Markets starting February 4, 2025.
Why It Matters
Procaps Group's delisting from Nasdaq signals financial instability, reducing visibility and liquidity for investors. Trading on the OTC market may lead to increased volatility and risk.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nasdaq will remove Procaps Group from its listings on February 4 due to non-compliance with financial reporting standards.
Why It Matters
The removal of Procaps Group from Nasdaq highlights regulatory compliance risks, potentially affecting investor confidence and signaling broader market challenges.
Source: Invezz
Market Sentiment:
Negative
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) received notice from Nasdaq on December 31, 2024, regarding a filing delinquency for its interim financial statements for the period ended June 30, 2024.
Why It Matters
Procaps Group's filing delinquency with Nasdaq raises concerns about its financial transparency and compliance, potentially affecting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) announced changes to its Board of Directors, restructuring of committees, and updates to its executive leadership following a recent Shareholders Meeting.
Why It Matters
Changes to board composition and executive leadership can impact strategic direction and operational efficiency, influencing investor confidence and stock performance for Procaps Group.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) announced key strategic transactions and governance updates to enhance its financial position and support long-term growth objectives.
Why It Matters
Procaps Group's strategic transactions and governance updates signal potential growth and improved financial stability, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
1 year ago
Quick Summary
Procaps Group (NASDAQ: PROC) faces potential suspension and delisting from Nasdaq due to failure to file the Form 20-F for 2023. The company may request a hearing to contest this action.
Why It Matters
Procaps Group faces potential delisting from Nasdaq due to failure to file required financial documents, signaling financial instability and raising concerns about its future viability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PROC Stock
What is Procaps Group S.A.'s (PROC) stock forecast for 2026?
Analyst forecasts for Procaps Group S.A. (PROC) are not currently available. The stock is trading at $0.02.
Is PROC stock a good investment in 2026?
According to current analyst ratings, PROC has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PROC stock?
Price predictions from Wall Street analysts for PROC are not currently available. The stock is trading at $0.02.
What is Procaps Group S.A.'s business model?
Procaps Group generates revenue through the development, manufacturing, and commercialization of a diverse range of pharmaceutical and nutritional products, leveraging advanced softgel technologies. The company's focus on research and development allows it to innovate and meet the needs of various sectors, including prescription and over-the-counter medications and nutritional supplements.
What is the highest forecasted price for PROC Procaps Group S.A.?
Price targets from Wall Street analysts for PROC are not currently available. The stock is trading at $0.02.
What is the lowest forecasted price for PROC Procaps Group S.A.?
Price targets from Wall Street analysts for PROC are not currently available. The stock is trading at $0.02.
What is the overall PROC consensus from analysts for Procaps Group S.A.?
The overall analyst consensus for PROC is neutral. Out of 1 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are PROC stock price projections?
Stock price projections, including those for Procaps Group S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 12:32 PM UTC